VIOLIN Logo
VO Banner
Search: for Help
About
Introduction
Statistics
VIOLIN News
Your VIOLIN
Register or Login
Submission
Tutorial
Vaccine & Components
Vaxquery
Vaxgen
VBLAST
Protegen
VirmugenDB
DNAVaxDB
CanVaxKB
Vaxjo
Vaxvec
Vevax
Huvax
Cov19VaxKB
Host Responses
VaximmutorDB
VIGET
Vaxafe
Vaxar
Vaxism
Vaccine Literature
VO-SciMiner
Litesearch
Vaxmesh
Vaxlert
Vaccine Design
Vaxign2
Vaxign
Community Efforts
Vaccine Ontology
ICoVax 2012
ICoVax 2013
Advisory Committee
Vaccine Society
Vaxperts
VaxPub
VaxCom
VaxLaw
VaxMedia
VaxMeet
VaxFund
VaxCareer
Data Exchange
V-Utilities
VIOLINML
Help & Documents
Publications
Documents
FAQs
Links
Acknowledgements
Disclaimer
Contact Us
UM Logo

Vaccine Detail

Double Inactivated whole SARS-CoV vaccine
Vaccine Information
  • Vaccine Name: Double Inactivated whole SARS-CoV vaccine
  • Target Pathogen: SARS-CoV
  • Target Disease: Severe Acute Respiratory Syndrome (SARS)
  • Type: Inactivated or "killed" vaccine
  • Status: Licensed
  • Host Species for Licensed Use: None
  • Host Species as Laboratory Animal Model: mouse
  • Antigen: whole virus (Tseng et al., 2012)
  • Immunization Route: Intramuscular injection (i.m.)
  • Description: Inactivated whole virus by formalin and Ultraviolet radiation, hence Double Inactivated (DI) Vaccine (Tseng et al., 2012)
Host Response

Mouse Response

  • Host Strain: Balb/c and C57BL/6 (Tseng et al., 2012)
  • Host age: 6-8 weeks (Tseng et al., 2012)
  • Host gender: Female (Tseng et al., 2012)
  • Vaccination Protocol: Each mouse received 100 µl injection of each vaccine intramuscularly on days 0 and 28. The injection was done at 1 µg, 0.5 µg, 0.25 µg, 0.125 µg of the vaccine (Tseng et al., 2012)
  • Immune Response: Increased titer of neutralizing antibodies and reduced viral titer (Tseng et al., 2012)
  • Side Effects: Eosinophil infiltration in the lung lesions after challenge, type-2 hypersensitivity reaction (Tseng et al., 2012)
  • Challenge Protocol: On day 56 after first vaccination, each mice was challenged challenged with 106TCID50/60 µl of SARS-CoV intranasally (IN) and euthanized on day 58 (Tseng et al., 2012)
  • Efficacy: protected (Tseng et al., 2012)
References
Tseng et al., 2012: Tseng CT, Sbrana E, Iwata-Yoshikawa N, Newman PC, Garron T, Atmar RL, Peters CJ, Couch RB. Immunization with SARS coronavirus vaccines leads to pulmonary immunopathology on challenge with the SARS virus. PloS one. 2012; 7(4); e35421. [PubMed: 22536382].